Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T21:27:22.171Z.
Calculation as of: 2026-10-06T21:27:22.171Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e0735a4b96e2b144a1c4082676ac09623fe8f2e34e42ff401d6c9377466895af
PEG RATIO
N/A
PEG RATIO AVG TTM
N/A
PEG RATIO AVG 3Y
N/A
PEG RATIO AVG 5Y
N/A
PEG RATIO AVG 10Y
N/A
PEG RATIO AVG 15Y
N/A
PEG RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$4.31B
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.64B
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LivaNova PLC (LIVN) | $4.12B | N/A | N/A | N/A | N/A |
| Relay Therapeutics, Inc. (RLAY)vs › | $4.11B | N/A | N/A | N/A | N/A |
| AbCellera Biologics Inc. (ABCL)vs › | $4.02B | N/A | N/A | N/A | N/A |
| ICU Medical, Inc. (ICUI)vs › | $3.99B | N/A | 25.16 | 11.69 | 23.54 |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.31B | N/A | N/A | N/A | N/A |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.31B | N/A | N/A | N/A | N/A |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.37B | N/A | N/A | N/A | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.48B | N/A | 0.39 | 0.39 | 0.39 |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.64B | N/A | N/A | N/A | N/A |
| BillionToOne, Inc. (BLLN)vs › | $4.60B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
22.1
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PEG RATIO |
|---|---|
| 2015-11-06 | 1.95 |
| 2015-11-05 | 1.94 |
| 2015-11-04 | 1.96 |
| 2015-11-03 | 1.99 |
| 2015-11-02 | 1.99 |
| 2015-10-30 | 1.97 |
| 2015-10-29 | 1.95 |
| 2015-10-28 | 2.02 |
| 2015-10-27 | 1.95 |
| 2015-10-26 | 1.94 |
| 2015-10-23 | 1.93 |
| 2015-10-22 | 1.84 |
| 2015-10-21 | 1.90 |
| 2015-10-20 | 1.91 |
| 2015-10-19 | 2.08 |
